Blockchain Registration Transaction Record

Aditxt's Pearsanta Advances Ovarian Cancer Test with DoD Grant Opportunity

Aditxt's subsidiary Pearsanta advances ovarian cancer detection with potential DoD grant, marking a leap in women's health innovation and early diagnosis.

This news is pivotal as it highlights a significant advancement in the early detection of ovarian cancer, a disease known for its late diagnosis and high mortality rates. The development of the Mitomic(R) Ovarian Test (MOT(TM)) by Pearsanta, Inc., a subsidiary of Aditxt, represents a potential breakthrough in women's health, offering hope for earlier intervention and better outcomes. The involvement of the U.S. Department of Defense underscores the test's importance and the trust in its scientific merit and innovation. For investors and stakeholders in the health technology sector, this announcement signals Aditxt's growing influence and commitment to addressing critical health challenges through collaborative innovation.